(Q43598881)

25 November 2017

title

Phosphorylated Smad2 and Smad3 signaling: Shifting between tumor suppression and fibro-carcinogenesis in chronic hepatitis C. (English)

1 reference

25 November 2017

0 references

1 reference

Takashi Yamaguchi

1

1 reference

25 November 2017

Koichi Matsuzaki

2

1 reference

25 November 2017

Ryosuke Inokuchi

3

1 reference

25 November 2017

Rinako Kawamura

4

1 reference

25 November 2017

Katsunori Yoshida

5

1 reference

25 November 2017

Miki Murata

6

1 reference

25 November 2017

Junichi Fujisawa

7

1 reference

25 November 2017

Nobuyoshi Fukushima

8

1 reference

25 November 2017

Michio Sata

9

1 reference

25 November 2017

Masayoshi Kage

10

1 reference

25 November 2017

Osamu Nakashima

11

1 reference

25 November 2017

Akihiro Tamori

12

1 reference

25 November 2017

Norifumi Kawada

13

1 reference

25 November 2017

Koichi Tsuneyama

14

1 reference

25 November 2017

Steven Dooley

15

1 reference

25 November 2017

Toshihito Seki

16

1 reference

25 November 2017

Kazuichi Okazaki

17

1 reference

25 November 2017

publication date

4 March 2013

1 reference

25 November 2017

1 reference

25 November 2017

volume

43

1 reference

25 November 2017

issue

12

1 reference

25 November 2017

page(s)

1327-1342

1 reference

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12082

Hepatitis C virus-induced hepatocarcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12082

Viral hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12082

Smad phosphoisoform signals in acute and chronic liver injury: similarities and differences between epithelial and mesenchymal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12082

Hepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12082

Emerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12082

Toll-like receptor signaling in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12082

TGF-beta signalling from cell membrane to nucleus through SMAD proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12082

Phospho-control of TGF-beta superfamily signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12082

Smad phosphoisoform signaling specificity: the right place at the right time

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12082

TGF-beta signaling: positive and negative effects on tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12082

Outcome of sustained virological responders with histologically advanced chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12082

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12082

Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12082

Cytokine receptors and signaling in hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12082

Less Smad2 is good for you! A scientific update on coffee's liver benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12082

Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12082

Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12082

Reversible Smad-dependent signaling between tumor suppression and oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12082

Smad2 and Smad3 phosphorylated at both linker and COOH-terminal regions transmit malignant TGF-beta signal in later stages of human colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12082

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12082

Functional genomics of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12082

Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12082

21 January 2018

Identifiers

DOI

10.1111/HEPR.12082

1 reference

25 November 2017

1 reference